Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Jiang, De-Qi; Wang, Huakun; Wang, Yan; Li, Mingxing; Jiang, Li-Lin; Wang, Yong

doi:10.1007/s10072-019-04050-8

Cited by 20 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heterogeneity test was executed by Q test (a P value less than .10 indicated a problem with heterogeneity) and I 2 statistics (a I 2 value of at least 50% was taken as indicator of substantial heterogeneity). [ 24 ] When heterogeneity existed ( I 2 > 50% and P < .10), the random-effect (RE) model was used for analysis, otherwise, the fixed-effect model was used for analysis. [ 25 ] The possibility of publication bias was tested by funnel plot.…”

Section: Methodsmentioning

confidence: 99%

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Chen¹,

Zheng²

2021

Medicine

View full text Add to dashboard Cite

Background: Atorvastatin treatment has been suggested as a therapeutic method for women with polycystic ovary syndrome (PCOS) in many clinical studies. Nonetheless, the effects of atorvastatin on insulin resistance in PCOS patients still remain controversial. Objective: The aim of this report was to evaluate the effects of atorvastatin therapy on the insulin resistance in the treatment of PCOS compared to that of placebo, in order to confer a reference for clinical practice. Methods: Randomized controlled trials (RCTs) of atorvastatin for PCOS published up to August, 2020 were searched. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated, and heterogeneity was measured by the I 2 test. Sensitivity analysis was also carried out. The outcomes of interest were as follows: fasting glucose concentration, fasting insulin level, homeostasis model assessment of insulin resistance (HOMA-IR) or body mass index (BMI) value. Results: Nine RCTs with 406 participants were included. The difference of fasting glucose concentration in PCOS patients between atorvastatin group and placebo group was not statistically significant (8 trials; SMD −0.06, 95% CI −0.31 to 0.20, P = .66). PCOS patients in atorvastatin group had lower fasting insulin level than those in placebo group (7 trials; SMD −1.84, 95% CI −3.06 to −0.62, P < .003). The homeostasis model assessment of insulin resistance (HOMA-IR) value showed significant decrease in the atorvastatin therapy compared to placebo (6 trials; SMD −4.12, 95% CI −6.00 to −2.23, P < .0001). In contrast to placebo, atorvastatin therapy did not decrease the BMI value significantly in PCOS patients (7 trials; SMD 0.12, 95% CI −0.07 to 0.31, P = .22). Conclusions: Atorvastatin therapy can reduce insulin resistance in the treatment of patients with PCOS. In addition, further large-sample, multi-center RCTs are needed to identify these findings.

show abstract

Section: Methodsmentioning

confidence: 99%

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Chen¹,

Zheng²

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…In the meantime, a number of studies have been published on rasagiline, some of which extended over several years (Hauser et al 2016 ; Jankovic et al 2014 ; Jiang et al 2020 ; Lew et al 2010 ; PSG 2002 ; Peretz et al 2016 ; Rascol et al 2005 , 2016 ; Stern et al 2004 ), notably: TEMPO, PRESTO, LARGO und ADAGIO:…”

Section: Rasagilinementioning

confidence: 99%

“…The tolerability of rasagiline is categorized as good (Jiang et al 2020 ), and the adverse reactions correspond to those of selegiline (both substances are irreversible MAO-B inhibitors). The substance is well tolerated by older patients (Goetz et al 2006 ).…”

Section: Rasagilinementioning

confidence: 99%

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

Jost

2022

J Neural Transm

View full text Add to dashboard Cite

Since the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson’s disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson’s disease, an option which is too often not appreciated properly.

show abstract

“…Авторы систематического обзора сделали вывод о том, что комбинированная терапия разагилином и леводопой превосходила монотерапию леводопой в отношении снижения общего балла по шкале UPDRS, баллов по подшкалам этой шкалы и суточного времени «выключения». Более того, оба вида лечения были одинаковы в безопасности и переносимости [25].…”

Section: эффект разагилина в комбинации с другими препаратами для лечunclassified

Разагилин: Ингибитор Мао-В Второго Поколения Для Лечения Болезни Паркинсона

Polivoda¹

2021

INJ

View full text Add to dashboard Cite

Болезнь Паркинсона (БП) — второе по распространенности нейродегенеративное заболевание, затрагивающее от 1 до 2 % людей старше 60 лет. Разагилин — мощный и необратимый ингибитор моноаминоксидазы типа В (MAO-В), который был одобрен для лечения БП. Разагилин ингибирует MAO-В более эффективно, чем селегилин, и имеет преимущество — прием один раз в день. В нескольких крупных рандомизированных плацебо-контролируемых исследованиях разагилин показал свою эффективность в качестве монотерапии при ранней БП и в качестве дополнительной терапии при поздней стадии БП. Было показано, что разагилин оказывает болезнь-модифицирующее, нейропротекторное и антиапоптотическое действие. Представлены данные о его эффективности при моторных нарушениях при болезни Паркинсона и скорости развития эффекта на фоне его назначения. При этом прием разагилина не сопровождается серьезными нежелательными явлениями как при монотерапии, так и в сочетании с леводопой и агонистами дофамина.

show abstract

Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Cited by 20 publications

References 48 publications

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

Разагилин: Ингибитор Мао-В Второго Поколения Для Лечения Болезни Паркинсона

Contact Info

Product

Resources

About